Printer Friendly

UNIMED TO MARKET UNIQUE NUTRITIONAL SUPPLEMENT DEVELOPED AT LEADING CANCER CENTER

 UNIMED TO MARKET UNIQUE NUTRITIONAL SUPPLEMENT
 DEVELOPED AT LEADING CANCER CENTER
 SOMERVILLE, N.J., April 9 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that it has signed an agreement with LifeScience Corp. of Austin, Texas for exclusive rights in the United States and Canada to market ONDROX(TM), a unique nutritional supplement. Initial distribution of ONDROX will begin within three to four months.
 ONDROX, which contains over 40 selected antioxidants, vitamins and minerals in a timed-release formulation, was developed by Dr. Thomas J. Slaga, a scientist at the University of Texas M.D. Anderson Cancer Center. The formulation has emerged from basic research and literature review. No human clinical trials have been conducted. Patent applications have been filed.
 Antioxidants, naturally contained in a number of fruits and vegetables, neutralize dangerous molecules called "free radicals" which can contribute to structural damage within the genetic material of human cells, thereby overwhelming normal cellular repair processes and opening the door to various diseases. The optimal combination of antioxidants and other nutrients along with the timed-release aspect of ONDROX offers additional benefits as a nutritional supplement. It is designed so the ingredients will be released slowly instead of either being partly absorbed in the body or eliminated before any benefit can be obtained.
 The typical American diet is deficient in many key nutrients, according to the United States Department of Agriculture. Approximately 50 percent of Americans currently take some form of nutritional supplement and product sales in this category approach $4 billion annually.
 "Nutritional support is gaining recognition as an important factor in maintaining good health," said Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer. "ONDROX provides UNIMED an exciting entry into this expanding segment of health maintenance."
 UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients.
 -0- 4/9/92
 /CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
 (UMED) CO: UNIMED Inc. ST: New Jersey, Texas IN: MTC SU:


TQ-SH -- NY067 -- 6854 04/09/92 14:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 9, 1992
Words:342
Previous Article:CALIFORNIA CHIP PRODUCER EMPLOYS TECHNOLOGY LICENSING, STRONG CUSTOMER RELATIONS TO DO GOOD BUSINESS IN JAPAN
Next Article:EARNINGS CONTINUE TO RISE AT UJB FINANCIAL


Related Articles
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO FORMULATE CANCER AND AIDS DRUGS
UNIMED ANNOUNCES APPROVAL OF MARINOL EFFICACY SUPPLEMENT BY FOOD AND DRUG ADMINISTRATION
UNIMED PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PRESIDENT/CEO
Glucarate Supplements Aid in Ex-Smokers' Fight Against Cancer
Unimed Pharmaceuticals Receives U.S. Patent to Cover Treatment for Dementia
Nutraceutix, Inc. Licenses Vitamin Plus to Distribute Patented Anti-Carcinogenic Nutritional Supplements.
The Cancer Wellness Institute Introduces Earthmends(TM) First Line of Dietary Supplements Formulated to Assist in Cancer Treatment and Provide a...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters